ABBV Chart

1 Month

	Date	Diff
	2025-05-05	-1.21 %
AbbVie (ABBV) stock declined by 1.21% following the FDA's approval of Teva Pharmaceuticals' interchangeable biosimilar SELARSDI™, which competes with AbbVie's reference product, Stelara®, highlighting increased competition in the biologics market. AbbVie (ABBV) stock declined by 1.21% amid a general focus on pharmaceutical stocks, driven by various market dynamics including trading volume fluctuations and potential investor reactions to competition and regulatory factors in the industry. AbbVie (ABBV) stock declined by 1.21% likely due to the announcement of a class action securities lawsuit against Cerevel Therapeutics Holdings, which implicates AbbVie in alleged securities fraud during its merger dealings with Cerevel, leading to concerns among investors about potential financial repercussions. Abbvie (ABBV) stock fell by 1.21% likely due to the FDA's approval of the biosimilar SELARSDI, which is marketed by Teva Pharmaceuticals and Alvotech as interchangeable with Abbvie’s Stelara, increasing competition and potentially impacting Abbvie's market share and revenues in the biologics segment. AbbVie (ABBV) stock declined by 1.21% amid a volatile biotech market, which often sees price fluctuations due to heavy investments in research and regulatory challenges related to drug approvals.
	2025-05-02	+2.65 %
AbbVie (ABBV) stock rose 2.65% due to positive post-earnings performance and an overall upward momentum in the market, indicating a favorable outlook for investors. AbbVie (ABBV) stock rose by 2.65% following positive results from a phase I trial of AMG 404, a monoclonal antibody targeting PD-1, which demonstrated promising safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors.
	2025-05-01	-0.9 %
AbbVie (NYSE:ABBV) stock declined by 0.9% despite a series of price target increases and buy ratings from various analysts, which may be attributed to profit-taking behaviors among investors following the recent earnings report and significant insider selling. AbbVie (ABBV) stock fell by 0.9% due to a combination of the company's high price-to-earnings ratio of 81.24 and competitive pressures within the pharmaceutical industry highlighted by the strong performances and trading volumes of rival companies such as Pfizer and Merck, which could impact investor sentiment and interest in ABBV. AbbVie (ABBV) stock fell by 0.9% following a day of trading that saw significant insider selling, which may have contributed to market concerns despite a recent increase in price target by Guggenheim and better-than-expected quarterly earnings. Abbvie (ABBV) stock declined by 0.9% likely due to ongoing legal issues related to allegations of misleading information surrounding its acquisition of Cerevel Therapeutics, which may have affected investor confidence. AbbVie Inc. (NYSE:ABBV) stock fell by 0.9% after the company's recent earnings report showed that while it surpassed analysts' estimates, continued insider selling and profit-taking may have influenced investor sentiment.
	2025-04-30	+0.82 %
AbbVie Inc. (NYSE:ABBV) stock rose 1.8% following the company’s announcement of better-than-expected quarterly earnings, reporting $2.46 earnings per share (EPS) compared to the $2.40 consensus estimate and a revenue of $13.34 billion which surpassed expectations. AbbVie (ABBV) stock rose by 0.82% following an upgrade in its price target from analysts at Evercore ISI, reflecting positive sentiment and potential for growth as several other analysts also issued favorable ratings and increased price targets for the stock. AbbVie (ABBV) stock rose by 0.82% following an increase in its price target from Morgan Stanley, which raised it from $241.00 to $250.00, indicating a potential upside and contributing to positive market sentiment.
	2025-04-29	+0.61 %
AbbVie (ABBV) stock saw a 0.61% increase, likely due to the favorable implications of its acquisition of Cerevel Therapeutics, which is under scrutiny for alleged securities fraud related to its merger process with AbbVie. The article discusses various class action lawsuits involving multiple companies, including accusations of misleading statements and nondisclosure of material facts, which may contribute to fluctuations in stock prices like AbbVie (ABBV) that increased by 0.61%. AbbVie's stock may have risen due to investor confidence related to the acquisition of Cerevel Therapeutics, as the lawsuits highlight the potential consequences of misleading information that affected stock valuations, suggesting that clarity and resolution could lead to positive movements in stock prices. AbbVie (ABBV) stock rose 0.61% following an upgrade from StockNews.com from a buy to a strong-buy rating, along with positive earnings results that surpassed analyst expectations and increased revenue compared to the previous year. AbbVie (ABBV) stock increased by 0.61%, reflecting its strong market performance over the past decade, which has outpaced the market with an average annual return of 11.78% and a current market capitalization of $344 billion. The stock likely rose due to investor confidence stemming from its historical performance and growth potential.
	2025-04-28	+3.38 %
AbbVie (ABBV) stock rose 3.38% as a result of investor optimism surrounding its acquisition of Cerevel Therapeutics, which was announced to significantly exceed the previous offering price, leading to a surge in confidence among shareholders. AbbVie (ABBV) stock rose 3.38% due in part to the anticipated benefits from its acquisition of Cerevel Therapeutics, which was revealed to be a profitable move for Bain Capital, creating investor interest and confidence. AbbVie (ABBV) stock rose by 3.38% to $185.96 due to increased trading volume and positive investor sentiment in the biotech sector, which includes prominent companies like AbbVie that are part of a list of stocks with high trading activity.
	2025-04-25	+3.15 %
AbbVie's stock rose 3.15% following stronger-than-expected first-quarter sales and adjusted earnings, prompting the company to raise its full-year adjusted EPS forecast despite potential risks from tariff impacts. AbbVie (ABBV) stock rose 3.15% after the company increased its 2025 earnings forecast due to robust sales in its immunology division following a strong quarterly report. AbbVie (ABBV) stock rose 3.15% after the company beat Wall Street's Q1 earnings expectations and raised its profit forecast for 2025, driven by strong sales of its newer drugs, Skyrizi and Rinvoq. AbbVie Inc. (ABBV) shares rose 3.15% due to positive analyst ratings and raised price targets from several investment firms, indicating strong market confidence in the stock's future performance. AbbVie (ABBV) stock rose by 3.15% due to investor optimism surrounding its acquisition of Cerevel Therapeutics, revealed through a lawsuit alleging misleading statements by Cerevel's shareholders prior to the acquisition announcement.
	2025-04-24	+1.88 %
AbbVie (ABBV) stock increased by 1.88% following a class action lawsuit announcement related to Cerevel Therapeutics, which alleged that material facts regarding AbbVie's acquisition interest were omitted during a stock offering, ultimately benefiting Bain Capital at the expense of other investors. The rise in AbbVie's stock price may be attributed to investor confidence in the company's strategic acquisitions and growth prospects in light of the merger with Cerevel, despite the ongoing lawsuit. AbbVie (NYSE: ABBV) stock rose by 1.88% to $172.58 amid a broader focus on pharmaceutical stocks due to their high trading volume, driven by factors such as ongoing clinical trials and regulatory developments in the industry. AbbVie (ABBV) stock rose by 1.88% due to its positioning as one of the leading biotech companies, with strong trading activity amid a focus on high-performing biotech stocks, which also reflects the market's overall interest in pharmaceutical innovations and developments.
	2025-04-23	+1.88 %
AbbVie (ABBV) stock increased by 1.88% due to strong anticipated earnings driven by consistent sales growth in products like Rinvoq and Skyrizi, offsetting declines from Humira, as the company prepares to announce earnings on April 25, 2025, with analysts projecting higher revenue and earnings per share compared to the previous year. AbbVie (ABBV) stock rose 1.88% following the initiation of coverage by Cantor Fitzgerald, which issued an overweight rating and a target price of $210.00, alongside positive price target adjustments and ratings upgrades from several other brokerages. AbbVie (ABBV) stock rose 1.88% as it is being evaluated against other top growth stocks, amidst concerns about a potential recession impacting the broader market. AbbVie (ABBV) stock rose by 1.88% ahead of its upcoming Q1 2025 earnings announcement, where analysts anticipate earnings of $2.51 per share and revenue of $12.91 billion, possibly motivated by positive market sentiment and favorable analyst ratings for the stock. AbbVie (ABBV) stock rose by 1.88% due to ongoing investor interest related to allegations of misleading statements and material omissions concerning a merger with Cerevel Therapeutics, prompting shareholders to consider legal action.
	2025-04-22	+2.13 %
AbbVie (ABBV) stock rose by 2.13% due to buyer confidence following the announcement of Cerevel Therapeutics' acquisition by AbbVie, which is perceived positively in the market amidst ongoing legal investigations related to Cerevel's stock offerings. The article discusses recent class action lawsuits against multiple companies, including allegations against Cerevel Therapeutics Holdings, Inc. regarding misleading statements related to AbbVie's acquisition interest; AbbVie (ABBV) stock may have risen by 2.13% due to increased investor confidence following news about its acquisition activities, suggesting positive market sentiment about its strategic moves.
	2025-04-21	-1.64 %
AbbVie (ABBV) stock fell by 1.64% amid the high volatility typical of biotech stocks, which often experience swings due to research and development risks and regulatory challenges. AbbVie (ABBV) stock experienced a decline of 1.64%, likely due to broader market movements and a focus on strategic adjustments in the healthcare sector by funds like Eaton Vance Worldwide Health Sciences Fund, which included reducing positions in other healthcare stocks. AbbVie (ABBV) stock experienced a decline of -1.64% due to the fallout from a class action lawsuit filed against Cerevel Therapeutics for alleged violations related to insider trading and misrepresentation during a secondary stock offering, which impacted investors' confidence in the related merger. AbbVie (ABBV) stock fell by 1.64% amid news of a class action securities lawsuit against Cerevel Therapeutics Holdings, Inc. regarding alleged securities fraud connected to AbbVie's acquisition of Cerevel, which raised concerns among investors about potential legal implications and their impact on AbbVie.
	2025-04-17	+0.76 %
AbbVie Inc. (NYSE:ABBV) stock increased by 0.76% despite a downgrade in Q1 2025 earnings estimates by Zacks Research, likely due to positive analyst ratings and a significant institutional ownership that supports investor confidence. AbbVie (ABBV) stock rose by 0.76% likely due to positive investor sentiment surrounding the company's involvement in the biopharmaceutical sector, particularly as Atea Pharmaceuticals announced significant developments and strategic decisions that could benefit the market and its stakeholders. AbbVie (ABBV) stock was up 0.76% last night, likely due to increased investor interest in pharmaceutical companies amid advancements in medical research and their potential for profitability. AbbVie (ABBV) stock saw a 0.76% increase, along with other pharmaceutical companies being highlighted as stocks to watch due to high trading volumes, suggesting investor confidence in potential advancements and profitability in the sector. AbbVie (ABBV) stock increased by 0.76% due to ongoing legal developments surrounding its acquisition of Cerevel Therapeutics, where allegations suggest deceptive practices related to the pricing and timing of the merger announcement that could impact investor confidence and market perception positively.
	2025-04-16	-2.9 %
AbbVie Inc. (NYSE:ABBV) stock fell by 2.9% due to ongoing concerns regarding the expiration of Humira's patent protection and overall market dynamics affecting investor confidence, despite the company achieving strong revenue growth and maintaining a solid dividend history. AbbVie (ABBV) stock fell 2.9% to a price of $172.50, entering oversold territory with a Relative Strength Index (RSI) of 29.1, suggesting heavy selling may be exhausting, which could indicate potential buying opportunities for bullish investors. AbbVie (ABBV) stock dropped by 2.9% due to increased volatility and trading dynamics typically associated with Biotech stocks, which are influenced by factors such as regulatory challenges and uncertainties surrounding product development. AbbVie (ABBV) stock fell 2.9% due to concerns arising from class action lawsuits related to misleading statements made by other companies, particularly influencing investor sentiments and market confidence. AbbVie (ABBV) stock fell by 2.9% due to concerns stemming from a class action lawsuit filed against Cerevel Therapeutics, which allegedly misled investors about AbbVie's interest in acquiring the company, impacting market perceptions related to AbbVie's value.
	2025-04-15	-1.28 %
AbbVie (ABBV) stock fell by 1.28% recently amid the volatility typical of biotech stocks, which are influenced by the high risks and costs of clinical trials, regulatory approvals, and the uncertain success of new medical treatments. AbbVie (ABBV) stock fell by 1.28% amidst a focus on pharmaceutical stocks, which are sensitive to regulatory changes and market demand, reflecting overall volatility in the healthcare sector. The decline could be attributed to factors impacting investor sentiment, such as competitive pressures or broader market trends that affect healthcare stocks.
	2025-04-14	+2.31 %
The article discusses a class action lawsuit filed against Cerevel Therapeutics for securities law violations related to its merger with AbbVie, suggesting that investor interest in AbbVie may have driven up its stock by 2.31%. AbbVie’s stock likely rose due to the anticipation of positive outcomes from its acquisition of Cerevel and possibly improved investor sentiment surrounding the merger. AbbVie (ABBV) stock rose by 2.31% likely due to the anticipated benefits from its upcoming acquisition of Cerevel Therapeutics, which was announced to occur shortly after a significant secondary stock offering that raised concerns about misleading practices related to the deal.
	2025-04-11	+0.49 %
AbbVie (ABBV) stock saw a 0.49% increase amidst a turbulent market influenced by President Trump's tariff announcements, as healthcare stocks generally demonstrated resilience and stability during periods of economic and geopolitical uncertainty. The increase in AbbVie's stock may be attributed to its position within the largely performing healthcare sector, which has shown positive movement compared to other industries amid the recent market volatility.
	2025-04-10	-3.14 %
AbbVie (ABBV) stock fell by 3.14% to $182.69 amid concerns likely linked to broader market trends affecting medical stocks and its relatively high valuation, reflected in a P/E ratio of 76.09 compared to its peers.
	2025-04-09	+2.37 %
AbbVie (ABBV) stock rose 2.37% recently amidst a broader focus on biotech stocks, driven by high trading volume and investor interest in innovative pharmaceutical developments. The increase in AbbVie's stock can be attributed to investor optimism regarding its diverse portfolio of treatments and continued growth potential in the biotech sector. AbbVie (ABBV) shares rose 2.37% as part of a broader interest in biotechnology stocks, which were highlighted by MarketBeat for their high trading volumes and potential due to ongoing developments and market dynamics within the sector. AbbVie (ABBV) stock rose by 2.37% as part of a broader trend in high-volume pharmaceutical stocks, likely driven by strong market performance and positive investor sentiment toward the healthcare sector.
	2025-04-08	-5.83 %
AbbVie (ABBV) stock fell by 5.83% to $186.58 as investors reacted to trading volume significantly exceeding average levels, alongside concerns regarding the company's high P/E ratio of 77.74 and recent market volatility affecting healthcare stocks.
	2025-04-07	-0.22 %
AbbVie (ABBV) stock experienced a decline of -0.22% due to potential investor concerns stemming from allegations of misleading statements related to the merger with Cerevel Therapeutics, where it is claimed that involved parties, including Bain Capital and Pfizer, may have acted unlawfully during a secondary stock offering. AbbVie (ABBV) stock experienced a decline of 0.22% amid trading, falling to $193.97, likely influenced by its trading volume being lower than average and the overall market dynamics affecting biotechnology stocks. AbbVie (ABBV) stock fell by 0.22%, closing at $186.58 amid higher trading volumes, likely influenced by broader market trends affecting pharmaceutical stocks, including competition and regulatory factors present within the industry. AbbVie (ABBV) stock declined by 0.22% to $186.58 amidst notable trading activity and performance metrics indicating vulnerability in its financial ratios, suggesting investor uncertainty and market volatility related to its products and earnings potential. AbbVie (ABBV) stock fell by 0.22% amid a broader trend of declining prices among major companies in the dividend stock sector, specifically experiencing a drop of $15.06 to $186.58 during trading hours. The decline may be attributed to overall market movements and investor sentiment affecting the stock's trading volume and performance in relation to its 50-day and 200-day moving averages.
	2025-04-02	-0.52 %
AbbVie (ABBV) stock fell 0.52% as part of general market volatility in biotech stocks, which is influenced by reliance on research developments, clinical trial results, and regulatory decisions. AbbVie (ABBV) stock decreased by 0.52% amid mixed trading activity in the pharmaceutical sector, influenced by broader market conditions and competition from other pharmaceutical companies, particularly Eli Lilly and Corcept Therapeutics, which are also under observation for their recent performance.
	2025-04-01	-1.55 %
AbbVie (ABBV) stock declined by 1.55% amid a broader focus on dividend stocks and increased trading activity among other companies, with no specific reasons given for AbbVie's performance. AbbVie (ABBV) stock dropped by 1.55% last night amidst volatility common in the biotech sector, potentially influenced by investor sentiment surrounding drug development challenges and regulatory approvals. The article primarily discusses the wealth rankings of billionaires, concluding with AbbVie (ABBV) stock's recent drop of -1.55%. The decline in AbbVie’s stock may be attributed to a combination of market fluctuations, investor sentiment, or specific company-related news, although the specific reasons are not detailed in the article provided.
	2025-03-31	+2.06 %
AbbVie (ABBV) stock rose by 2.06% to $203.80 as it remains one of the top biotech stocks to watch due to its strong portfolio of pharmaceutical products and significant trading volume. The increase may be attributed to investor enthusiasm around its diverse range of medications and ongoing market interest in biotech stocks, which have high potential for returns despite inherent risks. AbbVie Inc. (NYSE: ABBV) stock rose 2.06% as it received strong ratings and increased price targets from multiple analysts, contributing to positive investor sentiment despite some recent insider selling.
	2025-03-27	+0.71 %
AbbVie (ABBV) stock rose by 0.71% amid increased concerns and preparations regarding potential tariffs on pharmaceutical products, leading companies to expedite shipments of medicines to the U.S. in anticipation of these trade changes. AbbVie (ABBV) stock rose by 0.71% in a day when biotech stocks were under scrutiny due to their recent high trading volumes, indicating investor interest and potential optimism about the biotech sector's innovation and product pipelines. AbbVie (ABBV) stock rose by 0.71% amid positive market trends and heightened trading volume among leading pharmaceutical companies, reflecting investor confidence in ongoing pharmaceutical developments and innovations.
	2025-03-26	-0.02 %
AbbVie (ABBV) stock experienced a slight decline of -0.02% due to uncertainties surrounding its partnerships and financial performance, particularly in relation to collaborative efforts with OSE Immunotherapeutics and the broader market sentiment affecting biopharmaceutical companies. AbbVie (ABBV) stock experienced a slight decline of -0.02%, potentially influenced by the competitive advancements and positive growth reported by Alvotech, a company specializing in biosimilar medicines, which may indicate increasing pressure on AbbVie's market position. AbbVie (ABBV) stock was down by 0.02% due to uncertainties surrounding its competitive landscape, particularly with Alvotech making significant advancements in biosimilar development and achieving positive financial results, which may pose a challenge to AbbVie's market position.
	2025-03-25	-3.74 %
AbbVie (ABBV) stock declined by 3.74% after trading down $1.98 to $209.98 amid broader market movements among healthcare stocks, which are often influenced by regulatory changes and market dynamics specific to the healthcare sector.
	2025-03-24	-0.4 %
AbbVie (ABBV) stock decreased by 0.4% due to broader market fluctuations and potential investor concerns, despite its strong historical performance with an average annual return of 13.64% over the past decade.
	2025-03-21	-0.92 %
AbbVie (ABBV) stock declined by 0.92%, reaching $212.47 amid high volatility in the biotech sector; the drop could be attributed to fluctuations in trading volume and market reactions typical of the biotech industry's regulatory risks and uncertainties.
	2025-03-20	-0.14 %
AbbVie (ABBV) stock experienced a slight decline of -0.14%, potentially due to rising concerns over research and development expenses and financial results reported by Sionna Therapeutics, which recently licensed three clinical-stage assets from AbbVie, reflecting on the company’s high spending in this area.
	2025-03-19	-0.75 %
AbbVie (ABBV) stock decreased by 0.75% amidst overall attention on biotech companies, likely influenced by market volatility and the inherent risks associated with biotechnology research and regulatory processes. AbbVie (ABBV) stock experienced a decline of -0.75%, partly due to overall market volatility affecting tech stocks and investor sentiment regarding high-yield investments, as exemplified by the struggling YieldMax Ultra Income Strategy ETF.
	2025-03-18	-0.29 %
AbbVie (ABBV) stock fell by 0.29% after the company reported earnings of $2.16 per share, which missed analysts' expectations by $0.82, raising concerns about its financial performance despite upward revisions in future earnings estimates by Zacks Research.
	2025-03-14	+0.1 %
AbbVie (ABBV) stock rose 0.1% last night due to increased trading activity and interest in biotech stocks, which are currently under observation for their potential in pharmaceuticals and healthcare innovations.
	2025-03-13	-0.24 %
AbbVie (ABBV) stock fell by 0.24%, down $3.57 to $213.10, as part of a broader trend affecting biotech stocks due to high trading volumes and market fluctuations. The drop may be attributed to the high-risk nature of biotech investments, regulatory challenges, and ongoing fluctuations in trading volume relative to its average.
	2025-03-12	-0.72 %
Abbvie (ABBV) stock dropped by 0.72% due to overall market fluctuations and investor sentiment, as reflected in related trading activity and overall stock performance, but the specific reasons for this decrease are not detailed in the article. AbbVie (ABBV) stock declined by 0.72% due to overall market volatility typical of biotech stocks, which can be influenced by uncertainties in research and development, regulatory approvals, and market acceptance of innovations. AbbVie (ABBV) stock fell by 0.72% likely due to broader market movements and investor sentiment rather than specific news about the company itself, as the article primarily discusses the trades involving Boeing and Representative Jefferson Shreve. AbbVie (ABBV) stock fell by 0.72% due to a broader market reaction following disappointing quarterly earnings results and analysts lowering their target prices for the stock. AbbVie Inc. (NYSE: ABBV) experienced a 0.72% decline in its stock price, primarily due to the company's disappointing earnings report that missed analysts' expectations significantly by $0.82 per share.
	2025-03-11	-1.42 %
AbbVie (ABBV) stock fell by 1.42%, possibly due to concerns regarding competition and developments in the oncology sector, specifically related to its recent collaboration with Xilio Therapeutics, which is advancing tumor-activated immunotherapies that could impact AbbVie's market position. AbbVie (ABBV) stock fell by 1.42% due to overall market fluctuations affecting biotechnology stocks, despite having a strong trading volume and maintaining a significant market capitalization.
	2025-03-10	+1.11 %
AbbVie (ABBV) stock increased by 1.11% due to strong trading volume and interest in biotech stocks, which are known for their potential growth driven by innovations and developments in the pharmaceutical sector. AbbVie (ABBV) stock has seen a 1.11% increase, attributed to its strong performance in the immunology sector, particularly with drugs like Skyrizi and Rinvoq, ongoing investor interest in defensive sectors amidst economic uncertainty, and a recent partnership in the obesity treatment market, despite its high valuation compared to the broader market. AbbVie (ABBV) stock rose by 1.11% likely due to positive developments in the clinical programs and pipeline of Caribou Biosciences, which previously had a collaboration with AbbVie, hinting at the potential for future advancements in CAR-T cell therapies that could positively impact the industry and related stocks.
	2025-03-07	+1.68 %
AbbVie (ABBV) stock rose by 1.68%, reaching $209.40, as it is one of the biotech stocks being closely monitored given its recent trading volume, which reflects increased investor interest in the company’s pharmaceutical developments and market activity.
	2025-03-06	-0.37 %
AbbVie Inc. (ABBV) shares experienced a decline of 0.37% despite positive price target adjustments from several analysts, with the stock dropping partially due to a significant decrease in trading volume and reports of disappointing quarterly earnings that missed expectations. AbbVie (ABBV) stock decreased by 0.37%, trading at $210.43, amid a broader watch on biotech stocks which are often subject to market fluctuations and regulatory risks that can impact their share prices. The decline in AbbVie's stock could be attributed to its relatively high price-to-earnings ratio and market volatility affecting biotech stocks generally, which are known for their reliance on scientific innovation and lengthy regulatory processes. AbbVie (ABBV) stock fell by 0.37% amid growing concerns over the potential impact of President Trump's threatened tariffs on pharmaceutical imports, which could lead to increased drug costs and reduced access for patients. AbbVie (ABBV) stock was down 0.37% following a mixed set of outlook reports from analysts, including a neutral rating from Bank of America despite a price target increase, alongside concerns about the company's recent earnings miss.
	2025-03-04	-1.76 %
AbbVie (ABBV) stock dropped by 1.76% last night, which may be attributed to market fluctuations affecting medical stocks or investor reactions to the performance and news surrounding AbbVie and its competitors in the healthcare sector. AbbVie (ABBV) stock experienced a decline of 1.76% last night, despite outperforming the market over the past five years with an average annual return of 19.92%. The article does not specify the reasons for the stock's decline, so it could potentially be due to market volatility, investor sentiment, or specific company news.
	2025-02-27	+0.99 %
AbbVie (ABBV) stock rose by 0.99% last night, likely influenced by positive investor sentiment and developments related to its pipeline and pharmaceutical portfolio that are reassuring to shareholders. AbbVie (ABBV) stock rose by 0.99% due to increased trading volume and positive momentum in the biotech sector, which includes companies with innovative medical solutions and promising product pipelines.
	2025-02-26	-0.55 %
AbbVie (ABBV) stock fell by 0.55% after House members scrutinized prescription drug prices and accused pharmaceutical benefit managers (PBMs) of anti-competitive practices, highlighting a blame game between PBMs and drug companies that may negatively impact public perception and regulatory discussions in the pharmaceutical industry.
	2025-02-25	+0.03 %
Abbvie (ABBV) stock rose by 0.03% due to positive market sentiment surrounding the biotech sector, likely influenced by the stronger consensus rating and growth potential of related companies like argenx, which is seen as a robust investment compared to others like PharmaCyte Biotech. AbbVie (ABBV) stock experienced a slight increase of 0.03% attributed to its strong institutional ownership, higher revenue and earnings compared to Organigram, and favorable consensus price targets from analysts suggesting potential upside.
	2025-02-21	+0.6 %
The article discusses Dr. Mehmet Oz's plans to divest from several healthcare stocks, including AbbVie (ABBV), following his nomination to lead the Centers for Medicare & Medicaid Services, which could lead to a rise in AbbVie's stock by 0.6% last night due to reduced concerns about potential conflicts of interest affecting the company's business.
	2025-02-18	+1.75 %
AbbVie (ABBV) stock rose by 1.75% due to increased attention on biotech stocks, driven by developments in regulatory approvals, clinical trial results, and market demand for innovative medical treatments.
	2025-02-12	+0.61 %
AbbVie (ABBV) stock rose 0.61% following Xilio Therapeutics' announcement of a collaboration agreement with AbbVie to develop novel tumor-activated immunotherapies, which includes a $52 million upfront payment to Xilio, indicating investor confidence in future growth and innovation in cancer treatment. AbbVie (ABBV) stock rose by 0.61% following the announcement of a collaboration and option-to-license agreement with Xilio Therapeutics to develop innovative tumor-activated, antibody-based immunotherapies. The stock likely increased due to the positive market reaction to this partnership, which indicates potential for growth and advancement in cancer treatment.
	2025-02-11	+0.78 %
AbbVie (ABBV) stock rose by 0.78% due to positive developments surrounding Royalty Pharma PLC, which reported robust financial results and growth prospects, including a new $3 billion share repurchase program and an acquisition aimed at enhancing shareholder value. AbbVie (ABBV) stock rose by 0.78% due to stronger analyst ratings and a higher consensus target price compared to its competitor Alaunos Therapeutics, indicating a favorable outlook among investors.
	2025-02-07	-1.23 %
AbbVie (ABBV) stock fell by 1.23% amid a broader focus on several biotech stocks, indicating possible market volatility or investor sentiment affecting the sector; specific reasons for AbbVie's decline could include general market trends, investor reactions to earnings reports, or concerns over the pipeline and regulatory approvals of its pharmaceutical products.
	2025-02-06	+0.64 %
AbbVie Inc. (ABBV) stock rose 0.64% due to positive ratings from analysts, including multiple price target increases and a consensus rating of "Moderate Buy" from 24 firms, suggesting confidence in the company's future performance despite a recent earnings miss. AbbVie (ABBV) stock rose 0.64% following favorable Q1 2025 earnings projections and multiple analysts upgrading the stock's ratings and price targets, reflecting strong investor confidence in the company's future performance. The increase is attributed to positive earnings estimates and upgrades from analysts, signaling robust expectations for AbbVie's financial growth and stability.
	2025-02-05	+0.95 %
AbbVie (ABBV) stock increased by 0.95% following a price target raise from Guggenheim from $212.00 to $214.00, along with several other analysts upgrading their ratings and target prices, suggesting strong investor confidence in the stock's potential. AbbVie (ABBV) stock rose by 0.95% after analysts at Raymond James reaffirmed their "outperform" rating and increased the target price from $218.00 to $220.00, indicating a potential upside, while a consensus of analysts maintains a "Moderate Buy" rating on the stock. AbbVie (ABBV) stock rose by 0.95% following Jim Cramer's endorsement on "Mad Money," where he highlighted the company's potential and success with its immunosuppressive drugs, suggesting it's undervalued despite recent declines. The stock's increase can be attributed to positive analyst sentiment, particularly from Cramer, and AbbVie's strong performance in the biopharma sector, especially with its drugs Skyrizi and Rinvoq, providing reassurance to investors amid market uncertainties. AbbVie (ABBV) stock rose 0.95% following a target price increase from Truist Financial from $211.00 to $217.00, reflecting a positive outlook and a "buy" rating by the brokerage. AbbVie (ABBV) stock increased by 0.95% after UBS Group raised its price target from $181.00 to $190.00, indicating continued positive analyst sentiment toward the company's future performance despite a recent earnings miss.
	2025-02-04	-0.1 %
AbbVie (ABBV) stock fell by 0.1% as the company faces challenges following the loss of U.S. exclusivity for its top-selling drug, Humira, which had generated significant revenue for the company over the past two decades. AbbVie Inc. (ABBV) stock experienced a slight decline of 0.1% after last night's trading, largely due to its recent earnings report which showed a significant miss in earnings per share, falling short of analysts' expectations. AbbVie (ABBV) stock saw a slight decline of 0.1%, primarily due to broader market conditions affecting medical stocks, as they are sensitive to regulatory changes and economic fluctuations.
	2025-02-03	+3.39 %
AbbVie (ABBV) stock rose by 3.39% following the release of its Q4 financial results, which exceeded street estimates with strong revenue and earnings, particularly benefiting from robust sales of Rinvoq and Skyrizi, and positive future growth projections.
	2025-01-31	+4.7 %
Abbvie (ABBV) stock rose 4.7% due to positive investor sentiment related to improved economic conditions and overall market performance, contributing to a boost in healthcare sector stocks. AbbVie (ABBV) stock rose 4.7% last night, likely due to positive sentiment in the market following strong tech earnings and overall gains in U.S. stocks. AbbVie (ABBV) stock increased by 4.7% after the company reported better-than-expected adjusted earnings of $2.16 per share and fourth-quarter sales of $15.1 billion, surpassing analysts' predictions. AbbVie (ABBV) saw a 4.7% increase in its stock price following recent analyst ratings that generally favored the company, including multiple buy recommendations despite a slight reduction in its price target by Citigroup from $215.00 to $205.00, signaling investor confidence in its future performance. AbbVie (ABBV) stock rose 7% following strong fourth-quarter earnings, driven by solid sales of key immunology drugs, with overall operational sales increasing by 6.1% to $15.1 billion.
	2025-01-28	-1.18 %
AbbVie (ABBV) stock fell by -1.18% due to broader market trends favoring dividend stocks for their downside protection during tough economic times, potentially impacting investor sentiment and causing a shift in focus away from ABBV.
	2025-01-27	+3.88 %
AbbVie (ABBV) stock increased by 3.88% following its recognition as a Top Socially Responsible Dividend Stock by Dividend Channel, highlighting its strong 3.9% dividend yield and adherence to socially responsible investment criteria, which contributed to positive investor sentiment.
	2025-01-24	-0.22 %
AbbVie Inc. (ABBV) stock declined by 0.22% following a reduction in FY2025 earnings per share estimates by William Blair, which anticipated earnings of $12.02 instead of the previous forecast of $12.11. AbbVie (ABBV) stock was down 0.22% last night, which can be attributed to various market factors affecting pharmaceutical stocks, though specific reasons for the decline were not detailed in the article.
	2025-01-23	+0.87 %
AbbVie (ABBV) stock rose by 0.87% partly due to Cantor Fitzgerald's optimistic FY2025 earnings estimates, predicting higher earnings per share than the current consensus, indicating strong expected financial performance and positive analyst ratings, which have contributed to increased investor confidence.
	2025-01-22	-1.98 %
AbbVie (ABBV) stock fell by 1.98%, closing at $171.49, likely due to overall market volatility typically seen in biotech stocks influenced by uncertain outcomes in clinical trials and regulatory approvals. AbbVie (ABBV) stock dropped by 1.98% due to the overall market sentiment and performance comparison with other medical companies like Pathfinder Cell Therapy and CollPlant Biotechnologies, which may have influenced investor perception negatively. The article discusses the robust clinical trial pipeline for 5-HT2 agonists, highlighting advancements in precision medicine and their potential therapeutic applications, which may influence market stock movements, including AbbVie (ABBV) stock, which was down -1.98% recently likely due to competitive pressure and changing market dynamics in the pharmaceutical sector.
	2025-01-17	-1.23 %
AbbVie (ABBV) stock declined by 1.23% due to broader market conditions and potentially competitive pressures from companies like Cue Biopharma and Genmab A/S, which are showing promising prospects in the biopharmaceutical space and may be attracting investor interest away from AbbVie. AbbVie (ABBV) stock recently declined by 1.23% amidst ongoing challenges within the pharmaceutical sector, particularly regarding competition and performance issues affecting peer companies like Merck (MRK). The drop in AbbVie stock may be influenced by broader market sentiments regarding pharmaceutical stocks, as some companies, including Merck, are experiencing declining sales and increased competition for key products.
	2025-01-16	+1.37 %
AbbVie Inc. (NYSE:ABBV) stock rose by 1.37% following increased institutional investment, including a notable 16.5% increase in holdings by Signal Advisors Wealth LLC and positive earnings results that surpassed expectations along with a raised quarterly dividend.
	2025-01-15	-2.39 %
AbbVie (ABBV) stock fell by -2.39% due to broader market factors influencing dividend stocks and investor sentiment shifting towards alternative high-yield investments amidst changing interest rate conditions. AbbVie (ABBV) stock experienced a decline of 2.39% likely due to broader market pressures affecting the pharmaceutical sector and competitive challenges, particularly observed in Pfizer’s performance, which has been affected by declining sales from Covid-19 vaccine products and increased competition. AbbVie Inc. (NYSE:ABBV) stock fell by 2.39%, driven by a downgrade from Daiwa America from “strong-buy” to “hold,” alongside mixed analysts’ outlooks, despite its previous positive quarterly earnings report and upcoming dividend announcement.
	2025-01-13	+0.9 %
AbbVie (NYSE: ABBV) stock rose 0.9% following the announcement of a quarterly dividend increase from $1.55 to $1.64 per share, reflecting the company's 53 consecutive years of annual dividend raises and solid earnings performance. AbbVie (ABBV) stock rose by 0.9% following reports of increased institutional investments, specifically a 6.5% stake increase by the Czech National Bank, and positive earnings results that exceeded analysts' expectations.
	2025-01-10	-1.87 %
AbbVie Inc. (ABBV) stock declined by 1.87% following a downgrade in FY2024 earnings per share estimates from Leerink Partners, who reduced their forecast from $10.94 to $10.06, contributing to negative analyst sentiment and market reaction. AbbVie (ABBV) stock fell by 1.87% likely due to investor reactions to broader market trends or company-specific dynamics, with no specific incidents mentioned in the article regarding AbbVie itself. The article focuses primarily on Royalty Pharma plc's announcement of a significant internalization transaction aimed at enhancing shareholder value through a $3 billion share repurchase program and corporate governance improvements. AbbVie (ABBV) stock declined by 1.87% after Truist Financial reduced its price target from $215.00 to $211.00, although they maintained a "buy" rating, indicating market concerns despite the potential for future growth based on analyst ratings. AbbVie (ABBV) stock fell by 1.87% recently, likely influenced by broader market trends affecting pharmaceutical stocks, such as increased competition and underperformance compared to peers like Johnson & Johnson.
	2025-01-06	-0.62 %
AbbVie (ABBV) stock fell by 0.62% likely due to overall market fluctuations and investor sentiment influenced by comparisons with competing medical firms like Acumen Pharmaceuticals and argenx, which have shown differing financial strengths that may affect AbbVie's perceived performance in the biopharmaceutical sector. AbbVie Inc. (NYSE:ABBV) stock decreased by 0.62% following a report of CWA Asset Management Group LLC reducing its holdings in the company by 13.1%, alongside other institutional investment changes, which may have affected market confidence. AbbVie (ABBV) stock declined by 0.62% in response to a decrease in institutional investment as Boltwood Capital Management slightly reduced its position in the company. AbbVie (ABBV) stock fell by 0.62% due to a significant decrease in holdings by Legacy Wealth Management LLC, alongside other institutional trading activities, including insider share sales which may have created negative sentiment among investors.
	2025-01-03	+0.99 %
AbbVie Inc. (NYSE:ABBV) saw its stock rise by 0.99% last night due to increased institutional investor holdings and positive analyst ratings, despite some mixed views on its stock performance. The stock rose primarily because institutional investors, like Old Port Advisors, have been increasing their holdings, signaling confidence in AbbVie's potential, alongside favorable analyst ratings and an increase in their quarterly dividend. AbbVie Inc. (ABBV) stock rose by 0.99% following a significant increase in institutional investments, particularly from Versant Capital Management Inc, which raised its holdings in the company by 33.9% during the fourth quarter, along with positive earnings results and a favorable dividend announcement. AbbVie (ABBV) stock rose 0.99% due to increased institutional investment, positive quarterly earnings results that exceeded estimates, and a recently announced dividend hike, contributing to a favorable outlook from analysts.
	2025-01-02	+0.98 %
AbbVie (ABBV) stock rose by 0.98% likely due to increased demand and growth potential in the body contouring treatments market, where AbbVie is a prominent player, driven by rising acceptance of aesthetic procedures and advancements in non-invasive technologies.
	2024-12-30	-1.02 %
AbbVie Inc. (ABBV) stock fell by -1.02% following concerns over declining revenues from its flagship drug Humira due to the loss of patent exclusivity and increased competition from biosimilars, despite overall revenue growth in other segments.
	2024-12-26	-0.44 %
AbbVie (ABBV) stock fell by -0.44% due to concerns surrounding the implications of the Inflation Reduction Act, which allows Medicare to negotiate drug prices directly with manufacturers, potentially impacting the profitability of major pharmaceutical companies like AbbVie, particularly in light of ongoing issues like patent abuses and reduced future revenues from key products such as Humira. AbbVie (ABBV) stock fell by 0.44% due to a competitive landscape in the expanding breast cancer drugs market, where companies like Oncolytics Biotech and AstraZeneca are making significant advancements in treatment options, potentially influencing investor sentiment and Abbey's market performance.
	2024-12-20	+2.37 %
Shares of AbbVie Inc. (NYSE:ABBV) rose 2.37% following analyst upgrades and positive earnings results that exceeded expectations, despite some insider selling activity and a slight decline earlier in the day.
	2024-12-19	-0.87 %
AbbVie (ABBV) stock decreased by 0.87% after analysts raised price targets, suggesting potential for future appreciation, but sentiment may have shifted due to a senior vice president selling shares, indicating possible insider concerns. AbbVie (ABBV) stock fell by 0.87%, despite receiving an "overweight" rating from Piper Sandler with a target price of $220.00, likely due to existing market dynamics and prior selling activity by company insiders impacting investor sentiment.
	2024-12-18	-1.35 %
AbbVie (ABBV) stock dropped by 1.35% following a broader market trend where investor sentiment shifted negatively towards tech stocks like Broadcom due to concerns about waning demand for chips and slower AI progress, suggesting potential factors affecting the biotechnology sector as well.
	2024-12-17	+2.18 %
AbbVie (ABBV) stock rose 2.18% as the company aims to expand its cancer treatment portfolio, building on its success with immunology drugs like Humira and Skyrizi, which generated substantial revenue.
	2024-12-16	-1 %
AbbVie (ABBV) stock declined by 1.0% as it entered oversold territory, with a Relative Strength Index (RSI) reading of 29.6, indicating heavy selling pressure which could present buy opportunities for dividend investors.
	2024-12-12	-0.68 %
Abbvie (ABBV) stock fell by 0.68% likely due to ongoing market volatility linked to Bausch + Lomb's exploration of a potential sale amid mixed signals about private equity interest, which could impact related sectors and investor sentiment.
	2024-12-10	-0.51 %
AbbVie Inc. (ABBV) stock fell by 0.51% despite announcing an increased dividend, as concerns over the sustainability of its high payout ratio overshadow the positive dividend news and healthier cash flows.
	2024-12-06	+0.01 %
Abbvie Inc. (NYSE: ABBV) stock experienced a slight increase of 0.01%, driven by significant investments from institutional investors, positive quarterly earnings exceeding expectations, and a recently announced dividend increase.
	2024-12-02	-0.63 %
AbbVie (ABBV) stock fell by 0.63% likely due to investor sentiment shifts affected by contrasting performance evaluations between medical companies Nuvalent and Ironwood Pharmaceuticals, highlighting analysts' preference for Ironwood's higher potential upside, which may have influenced market perceptions of AbbVie's competitive landscape.
	2024-11-29	-0.08 %
AbbVie (ABBV) stock declined by 0.08% following mixed investor sentiment, despite institutional purchases indicating continued interest, as the company recently reported better-than-expected earnings and raised its quarterly dividend, but investor uncertainty may have contributed to the minor drop.
	2024-11-27	+1.07 %
AbbVie (ABBV) stock increased by 1.07% due to its attractiveness as a dividend stock, which helps investors balance their portfolios and mitigate risks during market volatility.
	2024-11-25	+0.06 %
AbbVie (ABBV) stock experienced a slight increase of 0.06% amidst a broader downturn in healthcare stocks, largely attributed to negative market sentiment following the US presidential election despite a general market rally. The slight increase in AbbVie's stock may stem from specific investor sentiment or reactions that diverged from the overall negative trend affecting healthcare stocks.
	2024-11-21	+2.37 %
AbbVie (ABBV) stock rose by 2.37% after Wells Fargo & Company raised its price target to $195.00, reflecting analysts' overall positive outlook on the stock and indicating potential upside based on recent strong earnings results and upgraded ratings from several brokerages. AbbVie (ABBV) stock rose by 2.37% due to favorable market expectations for its new drugs, Skyrizi and Rinvoq, which are gaining market share and are projected to significantly contribute to sales growth despite the decline in revenue from its former top-selling drug, Humira.
	2024-11-20	+0.71 %
AbbVie (ABBV) stock has increased by 0.71% likely due to the notable health policy shift following the nomination of Dr. Mehmet Oz, who has significant investments in healthcare stocks, raising investor optimism about potential favorable outcomes for healthcare companies amid his potential leadership at the Centers for Medicare & Medicaid Services. The article discusses the persistent issues faced by residents of Clare Island, particularly concerning the safety and accessibility of Roonagh pier, which affects their daily lives and economic activities. AbbVie (ABBV) stock rose by 0.71% possibly due to positive market reactions to company developments or broader market trends, but these details are not included in the provided article.
	2024-11-18	+0.78 %
AbbVie (ABBV) stock rose by 0.78% likely due to positive market sentiment tied to new developments in the biopharmaceutical sector, such as Mind Medicine's appointment of a qualified regulatory officer and planned Phase 3 clinical trials, which may signal potential future successes in psychiatric drug development. AbbVie (ABBV) stock rose by 0.78% following a quicker-than-expected return to top-line growth in the second quarter after losing patent exclusivity for its primary product, Humira. AbbVie (ABBV) stock rose 0.78% after Wolfe Research initiated coverage with an outperform rating and a $205 price target, joining other analysts in raising price targets and expressing positive sentiment about the company's financial performance and outlook. The increase in AbbVie shares is primarily due to favorable analyst ratings and strong recent earnings that exceeded expectations, along with a consistent dividend increase, which reflects confidence in the company's growth prospects.
	2024-11-14	-0.42 %
AbbVie (ABBV) stock experienced a decline of -0.42% due to general market volatility and potential uncertainties surrounding its earnings and dividends in a competitive pharmaceutical landscape.
	2024-11-12	-1.91 %
AbbVie (ABBV) stock fell by 1.91%, and over 12% overall, following the failure of its investigational anti-psychotic emraclidine in Phase II trials for schizophrenia, which may provide a competitive advantage to rival Bristol Myers Squibb (BMS) with their successful treatment candidate.
	2024-11-11	-12.57 %
AbbVie Inc (NYSE:ABBV) stock fell by 12.57% after the company released disappointing results from its Phase 2 EMPOWER trials of emraclidine, an oral treatment for schizophrenia, which may have raised concerns about the drug's efficacy. AbbVie Inc.'s (ABBV) stock fell by 12.57% after two Phase 2 trials for emraclidine, an oral treatment for schizophrenia, failed to meet their primary endpoints, disappointing Wall Street expectations for positive results. AbbVie Inc (NYSE:ABBV) stock fell by 12.57% after the company reported that two Phase 2 trials for emraclidine, its oral treatment for schizophrenia, failed to meet their primary endpoints. AbbVie (ABBV) stock fell by 12.57% following the announcement that two Phase 2 trials of its schizophrenia treatment emraclidine failed to meet their primary endpoints. AbbVie Inc. shares plunged over 12% after two mid-stage trials for its schizophrenia drug, emraclidine, failed to show significant improvement compared to a placebo, raising concerns about its recent $8.7 billion acquisition of Cerevel Therapeutics and impacting investor sentiment.
	2024-11-06	-0.24 %
AbbVie (ABBV) stock fell by 0.24% despite receiving multiple upgrades and positive analyst ratings because the overall market sentiment or other factors unrelated to its strong earnings or analyst recommendations may have influenced investor behavior.

1
500 / page